RadNet (RDNT) PT Raised to $95 at Raymond James

Raymond James analyst John Ransom raised the price target on RadNet (NASDAQ: RDNT) to $95.00 (from $75.00) while maintaining a Strong Buy rating.

The analyst comments "We are reiterating our Strong Buy rating and raising our price target to $95 (+$20; 16x 2028E EBITDA) following solid 3Q25 results, upbeat commentary on the 2026-2028 revenue and EBITDA trajectory. Supported by the detail from the analyst day, we are now modeling substantially higher revenue and adj. EBITDA (details below). We view the selloff (-1.33%) as being driven largely by the company’s conservative 2028 margin outlook (midpoint +1.25% consolidated), partly due to more muted Digital Health margins (~20% by 2028) than expected. To be clear, we think Digital Health as a standalone asset is a small appetizer (8% of 2028E Adj. EBITDA) vs. the core imaging sector (92% of 2028 adj. EBITDA). The good news is that the implied EV to 2028E EBITDA at 12.6x compares to peak valuation in the high teens."

You May Also Be Interested In

• Nurix (NRIX) PT Raised to $34 at Mizuho
• Iran's Qalibaf warns of all-out defence if US betrays deal
• Roth/MKM Upgrades Comstock Resources (CRK) to Neutral